source
- AI data emerges as a key hurdle in biopharma partnership dealsAs drug discovery becomes more intricate, the data used to train AI models is turning into a valuable asset in biopharma transactions. Companies are now negotiating not just drug candidates but the…
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…